Market Assessment - Strategic assessment of injectable, in situ gelling materials for ocular drug delivery

市场评估 - 用于眼部药物输送的可注射原位胶凝材料的战略评估

• 批准号: 556937-2020
• 负责人: Sheardown, Heather
• 金额: $ 1.09万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=706389
• 关键词: Market; Assessment; Strategic; assessment; injectable

Diseases in the eye are becoming increasingly common as the population ages; however, they remain notoriously difficult to treat. For instance, age-related macular degeneration (AMD) affects over 1.4 million Canadians and is the leading cause of vision loss in Canada. While the advent of anti-VEGF agents, a specific class of drugs, has significantly improved the prognosis and outcomes for many of these patients, they require intraocular injections every one to two months to maintain their effectiveness. Similarly, glaucoma, the second leading cause of blindness, requires patients to adhere to a challenging regime of eye drops multiple times each day, causing patients to struggle with compliance. Yet, if these conditions progress to vision loss, patients have been shown to require greater assistance with daily activities, suffer high incidences of depression and anxiety, and have twice the risk of falls; this all results in a substantial decrease in their quality of life. We propose a new delivery system that would work with different therapeutics for a variety of conditions. This would reduce treatments from monthly to bi-annually, increasing both safety and convenience for patients and reducing the burden on the healthcare system. We request funds to complete a Market Assessment to determine which ocular disease condition is best suited to initial development, which will allow us to then create a business plan for successful technology transfer and commercialization.

随着人口老龄化，眼部疾病变得越来越普遍;然而，众所周知，这些疾病仍然难以治疗。例如，年龄相关性黄斑变性（AMD）影响了140多万加拿大人，是加拿大视力丧失的主要原因。虽然抗VEGF药物（一种特定类别的药物）的出现显着改善了许多患者的预后和结局，但它们需要每一到两个月进行眼内注射以维持其有效性。同样，青光眼，第二大致盲原因，需要患者坚持每天多次滴眼液的挑战性方案，导致患者难以依从。然而，如果这些疾病进展到视力丧失，患者已经被证明需要更多的日常活动帮助，抑郁和焦虑的发生率很高，并且福尔斯的风险增加一倍;这都导致他们的生活质量大幅下降。我们提出了一种新的输送系统，将与不同的治疗方法用于各种条件。这将把治疗从每月一次减少到每两年一次，增加患者的安全性和便利性，并减轻医疗保健系统的负担。我们申请资金以完成市场评估，以确定哪种眼病最适合初始开发，这将使我们能够为成功的技术转让和商业化制定商业计划。